NO20045677L - Inhibitorer av JAK- og CDK2-proteinkinaser - Google Patents

Inhibitorer av JAK- og CDK2-proteinkinaser

Info

Publication number
NO20045677L
NO20045677L NO20045677A NO20045677A NO20045677L NO 20045677 L NO20045677 L NO 20045677L NO 20045677 A NO20045677 A NO 20045677A NO 20045677 A NO20045677 A NO 20045677A NO 20045677 L NO20045677 L NO 20045677L
Authority
NO
Norway
Prior art keywords
inhibitors
protein kinases
jak
compounds
cdk2 protein
Prior art date
Application number
NO20045677A
Other languages
English (en)
Other versions
NO20045677D0 (no
Inventor
Brian E Ledford
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of NO20045677D0 publication Critical patent/NO20045677D0/no
Publication of NO20045677L publication Critical patent/NO20045677L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

Foreliggende oppfinnelse tilveiebringer en forbindelse med formel I: eller et farmasøytisk akseptabelt salt derav. Disse forbindelser er inhibitorer av proteinkinaser, spesielt inhibitorer av mammalske JAK- og CDK2-proteinkinaser. Oppfinnelsen tilveiebringer også farmasøytisk akseptable sammensetninger omfattende forbindelsene ifølge oppfinnelsen og fremgangsmåter for å anvende disse forbindelser og sammensetninger ved behandling av en rekke proteinkinase-medierte forstyrrelser.
NO20045677A 2002-05-30 2004-12-28 Inhibitorer av JAK- og CDK2-proteinkinaser NO20045677L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38453802P 2002-05-30 2002-05-30
PCT/US2003/016900 WO2003101989A1 (en) 2002-05-30 2003-05-30 Inhibitors of jak and cdk2 protein kinases

Publications (2)

Publication Number Publication Date
NO20045677D0 NO20045677D0 (no) 2004-12-28
NO20045677L true NO20045677L (no) 2005-02-28

Family

ID=29712051

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20045677A NO20045677L (no) 2002-05-30 2004-12-28 Inhibitorer av JAK- og CDK2-proteinkinaser

Country Status (12)

Country Link
US (1) US7122552B2 (no)
EP (1) EP1507779A1 (no)
JP (2) JP2005528443A (no)
KR (1) KR20050013562A (no)
CN (1) CN1665810A (no)
AU (1) AU2003231880A1 (no)
CA (1) CA2487679A1 (no)
MX (1) MXPA04011956A (no)
NO (1) NO20045677L (no)
PL (1) PL374023A1 (no)
RU (1) RU2004138819A (no)
WO (1) WO2003101989A1 (no)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
IL166241A (en) 2002-07-29 2011-12-29 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds for use in the treatment of autoimmune diseases
ES2421139T3 (es) 2003-07-30 2013-08-29 Rigel Pharmaceuticals, Inc. Compuestos de 2,4-pirimidindiamina para su uso en el tratamiento o la prevención de enfermedades autoinmunitarias
EA200801812A1 (ru) * 2003-09-17 2009-06-30 Янссен Фармацевтика Н.В. Сопряженные гетероциклические соединения
AU2011253635B2 (en) * 2003-09-17 2014-10-30 Janssen Pharmaceutica, N.V. Fused heterocyclic compounds
EP1713814A1 (en) 2003-12-17 2006-10-25 SGX Pharmaceuticals, Inc. Bicyclic pyrazolo-fused compounds as protein kinase modulators
WO2005123111A2 (en) * 2004-06-21 2005-12-29 Exelixis, Inc. Maxs as modifiers of the axin pathway and methods of use
ES2337496T3 (es) 2005-01-19 2010-04-26 Rigel Pharmaceuticals, Inc. Profarmacos de compuestos de 2,4-pirimidindiamina y sus usos.
US20070203161A1 (en) * 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
AU2006254840B2 (en) 2005-06-08 2012-08-02 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
ES2622493T3 (es) * 2006-02-24 2017-07-06 Rigel Pharmaceuticals, Inc. Composiciones y métodos para la inhibición de la ruta de JAK
EP2012815A4 (en) * 2006-04-14 2009-12-09 Massachusetts Inst Technology IDENTIFICATION AND MODULATION OF MOLECULAR PATHWAYS THAT INDUCE THE PLASTICITY OF THE NERVOUS SYSTEM
KR101172936B1 (ko) * 2006-07-14 2012-08-16 노파르티스 아게 Ａｌｋ-5 억제제로서의 피리미딘 유도체
AU2007338574A1 (en) * 2006-11-01 2008-07-03 Vertex Pharmaceuticals Incorporated Tricyclic heteroaryl compounds useful as inhibitors of Janus kinase
ES2369596T3 (es) * 2007-05-04 2011-12-02 Astrazeneca Ab Derivados de amino-tiazolil-pirimidina y su uso para el tratamiento del cáncer.
EP2265607B1 (en) * 2008-02-15 2016-12-14 Rigel Pharmaceuticals, Inc. Pyrimidine-2-amine compounds and their use as inhibitors of jak kinases
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
ES2546502T3 (es) 2008-04-16 2015-09-24 Portola Pharmaceuticals, Inc. 2,6-Diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o JAK quinasas
EP2271631B1 (en) * 2008-04-22 2018-07-04 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
EP2370437B1 (en) * 2008-11-25 2013-09-04 Nerviano Medical Sciences S.r.l. Bicyclic pyrazole and isoxazole derivatives as antitumor and antineurodegenerative agents
EP2396004A4 (en) * 2009-02-11 2012-07-25 Reaction Biology Corp SELECTIVE KINASE HEMMER
US8663210B2 (en) 2009-05-13 2014-03-04 Novian Health, Inc. Methods and apparatus for performing interstitial laser therapy and interstitial brachytherapy
JO3030B1 (ar) * 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
MX2012000709A (es) * 2009-07-15 2012-03-16 Abbott Lab Inhibidores de pirrolopiridina de cinasas.
CA2768543C (en) * 2009-07-28 2017-06-20 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
WO2011025947A1 (en) * 2009-08-28 2011-03-03 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
UY33213A (es) * 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
EP2635557A2 (en) 2010-11-01 2013-09-11 Portola Pharmaceuticals, Inc. Nicotinamides as jak kinase modulators
US9198911B2 (en) 2010-11-02 2015-12-01 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
WO2013149194A1 (en) * 2012-03-29 2013-10-03 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
IN2014CN04065A (no) 2011-11-23 2015-09-04 Portola Pharm Inc
WO2013113762A1 (en) 2012-01-31 2013-08-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and kits for predicting the risk of having a cutaneous melanoma in a subject
PT2841428T (pt) 2012-04-24 2018-11-29 Vertex Pharma Inibidores de adn-pk
WO2014013014A1 (en) 2012-07-18 2014-01-23 Fundació Privada Centre De Regulació Genòmica (Crg) Jak inhibitors for activation of epidermal stem cell populations
EP2903970A4 (en) 2012-10-08 2016-11-30 Portola Pharm Inc SUBSTITUTED PYRIMIDINYL KINASE INHIBITORS
DK3527563T3 (da) 2013-03-12 2021-12-06 Vertex Pharma Dna-pk-inhibitorer
SG11201602962PA (en) 2013-10-17 2016-05-30 Vertex Pharma Co-crystals of (s)-n-methyl-8-(1-((2'-methyl-[4,5'-bipyrimidin]-6-yl)amino)propan-2-yl)quinoline-4-carboxamide and deuterated derivatives thereof as dna-pk inhibitors
SG11201608242XA (en) * 2014-04-04 2016-10-28 Syros Pharmaceuticals Inc Inhibitors of cyclin-dependent kinase 7 (cdk7)
US9527845B2 (en) * 2014-12-30 2016-12-27 Novira Therapeutics, Inc. Derivatives and methods of treating hepatitis B infections
WO2017091681A1 (en) 2015-11-24 2017-06-01 Aclaris Therapeutics, Inc. Selective kinase inhibitors
WO2018041989A1 (en) 2016-09-02 2018-03-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating refractory celiac disease type 2
MX2019003317A (es) 2016-09-27 2019-08-05 Vertex Pharma Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk).
US10759865B2 (en) 2017-08-22 2020-09-01 Eyal Levit Treatment of diabetes mellitus
US20200199136A1 (en) * 2017-08-28 2020-06-25 Acurastem Inc. Pikfyve kinase inhibitors
CN108586341B (zh) * 2018-05-25 2020-05-08 天津商业大学 酰胺类化合物和其药用盐及其制备方法和药物用途
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
EP3947737A2 (en) 2019-04-02 2022-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
EP3955920A1 (en) 2019-04-16 2022-02-23 Institut National de la Santé et de la Recherche Médicale (INSERM) Use of jak inhibitors for the treatment of painful conditions involving nav1.7 channels
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN114605390A (zh) * 2020-12-04 2022-06-10 上海凌达生物医药有限公司 具有cdk激酶抑制活性的化合物、其药物组合物和用途
WO2023222565A1 (en) 2022-05-16 2023-11-23 Institut National de la Santé et de la Recherche Médicale Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK27383A (da) 1982-02-17 1983-08-18 Lepetit Spa Fremgangsmaade til fremstilling af pyrazol(4,3-c)pyridiner
GB0016877D0 (en) * 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
WO2003101989A1 (en) 2003-12-11
US20030236244A1 (en) 2003-12-25
US7122552B2 (en) 2006-10-17
KR20050013562A (ko) 2005-02-04
JP2011006494A (ja) 2011-01-13
PL374023A1 (en) 2005-09-19
MXPA04011956A (es) 2005-03-31
CN1665810A (zh) 2005-09-07
CA2487679A1 (en) 2003-12-11
NO20045677D0 (no) 2004-12-28
EP1507779A1 (en) 2005-02-23
JP2005528443A (ja) 2005-09-22
AU2003231880A1 (en) 2003-12-19
RU2004138819A (ru) 2005-06-10

Similar Documents

Publication Publication Date Title
NO20045677L (no) Inhibitorer av JAK- og CDK2-proteinkinaser
ATE473980T1 (de) Triazolopyridazine als proteinkinase-inhibitoren
NO20051100L (no) Pyrazolsammensetninger anvendelige som GSK-3-inhibitorer
AU2003297160A1 (en) Benzisoxazole derivatives useful as inhibitors of protein kinases
NO20073140L (no) Pyrrolopyraziner og pyralopyraziner som er nyttige som inhibitorer av proteinkinaser
HK1065033A1 (en) Thiazole compounds useful as inhibitors or proteinkinases
ATE371656T1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
NO20055496L (no) Pyrazolokinazolinderivater, metoder for deres fremstilling og deres anvendelse som kinaseinhibitorer
NO20071320L (no) Pyrazolsubstituerte aminoheteroarylforbindelser som protein kinase inhibitorer.
MXPA03010961A (es) Compuestos de tiazol utiles como inhibidores de proteinas cinasas.
NO20052888L (no) Diamintriazoler anvendelige som inhibitorer av proteinkinaser
MX2007014619A (es) Pirrolopiridinas de utilidad como inhibidores de proteina quinasa.
IL181987A0 (en) Diaminotriazole derivatives and pharmaceutical compositions containing the same
DE60332433D1 (de) Azolylaminoazine als proteinkinasehemmer
DE60332604D1 (de) Azolylaminoazine als proteinkinasehemmer
ATE365733T1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
EP1485381B8 (en) Azolylaminoazine as inhibitors of protein kinases
TW200514776A (en) Aminotriazole compounds useful as inhibitors of protein kinases
NO20082026L (no) Deazapuriner som er nyttige som inhibitorer for Janus-kinaser
NO20025601L (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
NO20072567L (no) Triazoler nyttige som proteinkinase-inhibitorer
NO20082508L (no) Aminopyrimidiner anvendelige som kinaseinhibitorer
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
MXPA05009151A (es) Inhibidores de cinasa heterociclica.
WO2004072029A3 (en) Pyrazolopyridazines useful as inhibitors of protein kinases

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application